SEC Filing Summary: BioSig Technologies, Inc. (BSGM)
Business Context and Reporting Period
This Form 8-K Current Report was filed by BioSig Technologies, Inc. on February 7, 2023, covering events occurring on February 2, 2023. The filing primarily addresses significant changes in executive leadership and the completion of a private placement of equity securities.
Key Financial Metrics and Capital Events
- Capital Raise: On January 23, 2023, the Company sold 1,665,384 shares of Common Stock and a warrant to purchase 832,692 shares to an accredited investor for total consideration of approximately $1.3 million ($1,299,998.75).
- Share Price: The purchase price for the common stock was $0.7806 per share. The warrant exercise price is $0.7181 per share.
- Compensation Costs: The new CFO, Steve Buhaly, has an annual base salary of $100,000. The departing CFO, Steve Chaussy, is eligible for up to 250,000 restricted shares contingent on board and stockholder approval.
- Financial Statements: This filing does not contain revenue, profit, cash flow, or debt metrics. The filing text does not provide a clear value for these operational financial indicators.
Material Changes and Executive Transitions
- Departure of CFO: Steve Chaussy's employment terminated effective February 2, 2023, with a separation date set for April 28, 2023, or earlier. He will receive continued salary and benefits through the separation date.
- Severance Package: Mr. Chaussy is eligible to receive 125,000 restricted shares immediately (Tranche A) and an additional 125,000 restricted shares (Tranche B) upon execution of a supplemental release agreement. All shares are fully vested upon grant.
- Appointment of New CFO: Steve Buhaly was appointed Chief Financial Officer, commencing employment on February 6, 2023. He brings over 30 years of experience, including 15 years as a CFO at companies such as Qorvo Inc. and Planar Systems Inc.
- New CFO Compensation: Mr. Buhaly is eligible for stock options to acquire up to 250,000 shares, subject to a twelve-month quarterly vesting schedule and board approval of the 2023 Long-Term Incentive Plan.
Guidance, Risks, and Contingencies
- Contingent Equity Grants: The issuance of restricted shares to the departing CFO and stock options to the new CFO is contingent upon the approval of the Company's 2023 Long-Term Incentive Plan by stockholders.
- Unregistered Securities: The Company issued a warrant to Laidlaw & Company (UK) Ltd. for 124,904 shares as a tail provision for the January PIPE transaction. This was issued under Section 4(a)(2) exemption.
- Regulatory Disclosure: The press release regarding the CFO transition is furnished under Regulation FD but is not deemed "filed" for liability purposes under Section 18 of the Exchange Act.
Key Facts for Investor Verification
- Verify the status of the 2023 Long-Term Incentive Plan approval, as it is a prerequisite for the equity grants to both the departing and incoming CFOs.
- Confirm the dilution impact of the 1,665,384 shares sold in the January PIPE and the associated warrants (832,692 shares).
- Monitor the vesting schedule and exercise price of the 250,000 stock options granted to the new CFO, Steve Buhaly.
- Review the full text of the General Release and Severance Agreement (Exhibit 10.1) for specific clawback provisions or additional conditions not summarized in the 8-K.